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Besides demonstrated efficacy, selective serotonin reuptake inhibitors (SSRIs) hold other
advantages over earlier antidepressants such as greater tolerability and a wider range of
clinical applications. However, there is a growing body of clinical evidence which suggests
that SSRIs could, in some cases, be associated with a withdrawal reaction upon cessation
of regular use. In addition to sensory and gastrointestinal-related symptoms, the somatic
symptoms of the SSRI discontinuation syndrome include dizziness, lethargy, and sleep
disturbances. Psychological symptoms have also been documented, usually developing
within 1–7 days following SSRI discontinuation. The characteristics of the discontinuation
syndrome have been linked to the half-life of a given SSRI, with a greater number of reports
emerging from paroxetine compared to other SSRIs. However, many aspects of the neu-
robiology of the SSRI discontinuation syndrome (or SSRI withdrawal syndrome) remain
unresolved. Following a comprehensive overview of the clinical evidence, we will discuss
the underlying pathophysiology of the SSRI discontinuation syndrome and comment on
the use of animal models to better understand this condition.
Keywords: antidepressant treatment, selective serotonin reuptake inhibitor, SSRI discontinuation syndrome, SSRI
withdrawal syndrome, animal models, clinical evidence, serotonin
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are widely used
in the treatment of depressive disorders (Petersen et al., 2002;
Chaudhry et al., 2011) and anxiety disorders (van der Linden
et al., 2000; Hedges et al., 2007). Total SSRI prescription volume
increased threefold between 1995/1996 and 2006/2007 (Lockhart
and Guthrie, 2011). Despite this, the use of SSRIs is not with-
out flaws. Apart from potential adverse side effects arising from
long-term antidepressant treatment, as well as issues of relapse,
and recurrence following remission of a depressive episode (Rucci
et al., 2011; Rush et al., 2012), the existence of a SSRI discontin-
uation syndrome (also known as SSRI withdrawal syndrome) has
been suggested in some cases. A decade ago, Harvey et al. (2003)
highlighted that although significant progress had been made to
uncover the pathophysiology of depression and the mechanisms
of actions of SSRIs, the neurobiology of SSRI discontinuation
syndrome had not been comprehensively addressed. Following
an overview of the clinical evidence, we will discuss the possi-
ble molecular mechanisms implicated in the pathology of SSRI
discontinuation syndrome, and comment on the use of animal
models to better understand this condition.
CLINICAL EVIDENCE OF SSRI DISCONTINUATION
SYNDROME
About 15 years ago, Zajecka et al. (1997) proposed a definition of
the SSRI discontinuation syndrome as the onset of a cluster of
symptoms following the discontinuation of a SSRI, not attribut-
able to other causes (i.e., concomitant medication, illness). Along
with sensory and gastrointestinal symptoms, the SSRI discontin-
uation syndrome includes somatic symptoms such as dizziness,
lethargy, and sleep disturbances, as well as psychological symp-
toms such as anxiety/agitation, irritability, and poor concentration
(Warner et al., 2006; Haddad and Anderson, 2007). The literature
on these symptoms initially consisted mainly of case reports (Cou-
pland et al., 1996; Price et al., 1996; Schatzberg et al., 1997; Bryois
et al., 1998; Goldstein et al., 1999). Haddad (1997) reviewed 47
separate reports of SSRI discontinuation syndrome, 30 of which
involved paroxetine compared to only seven involving fluoxetine,
despite the latter being prescribed more frequently. Black et al.
(2000) identified 53 different symptoms within the condition
(with dizziness being the most common) and proposed a diagnos-
tic criteria for SSRI discontinuation syndrome that requires two
or more of the described symptoms developing within 1–7 days of
discontinuation (or reduction in dosage) of an SSRI after at least
1 month of treatment.
These case reports have since been followed up by a number of
controlled studies (i.e., prospective studies, with a randomized,
double-blind interruption period, which included a systematic
method for discontinuation symptoms data collection). For exam-
ple, using the Discontinuation Emergent Signs and Symptoms
(DESS) checklist, Rosenbaum et al. (1998) assessed the effects
of a 1-week placebo substitution period in patients diagnosed
with unipolar depressive disorder who had been maintained on
fluoxetine, sertraline, or paroxetine for similar periods of time
(∼11 months). Following treatment interruption, there was a sig-
nificant increase in the number of DESS items observed in the
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sertraline- and paroxetine-treated patients. In contrast, this was
not detected in fluoxetine-treated patients. Another double-blind
trial found that placebo substitution for paroxetine was associ-
ated with increased frequency and severity of specific physical and
psychological symptoms, which arose as early as after the second
missed dose (Michelson et al., 2000). In that trial, patients with
a history of depression had been undergoing SSRI treatment for
similar periods of time (∼12–15 months) and were equivalent on
several parameters (e.g., similar baseline symptom severity). The
discontinuation symptoms seemed to be specific to paroxetine
in this study, since patients treated with sertraline or fluoxe-
tine did not exhibit discontinuation syndrome within the 5-day
placebo substitution period. However, since sertraline and fluox-
etine (but not paroxetine) have active metabolites with half-lives
around 2–3 and 7–15 days respectively (Table 1), the effects of
longer withdrawal periods are worth assessing in future stud-
ies. In the case of fluoxetine, it is possible that discontinuation
symptoms may emerge when the levels of the active metabolite
decrease after 15 days and beyond. Consistent with that possibility,
Zajecka et al. (1998) found a small increase in reports of dizziness
among patients who discontinued fluoxetine 4 and 6 weeks after
placebo substitution. Bogetto et al. (2002) investigated 97 out-
patients diagnosed with dysthymic disorder who were instructed
to stop their medication (paroxetine or fluoxetine) after a suc-
cessful treatment period of at least 8 weeks. With a mean time of
onset of symptoms of 2 days after drug discontinuation, discon-
tinuation syndrome was reported by 27% of patients (of which
85% had been treated with paroxetine compared to only 15%
treated with fluoxetine). Analyzing randomized controlled stud-
ies of escitalopram and paroxetine for the treatment of anxiety
disorders (in which treatments were followed by a prospectively
defined discontinuation period), Baldwin et al. (2007) reported
that individuals taking either SSRI showed more discontinuation
symptoms compared to placebo. Following a 12–24 week treat-
ment period, patients were abruptly switched to placebo and were
assessed using the DESS checklist 1 and 2 weeks after drug ces-
sation. Overall, paroxetine withdrawal induced significantly more
discontinuation symptoms than escitalopram.
There are a variety of symptoms associated with paroxetine
withdrawal as Murata et al. (2010) recently provided based on
observations of a group of Japanese outpatients (n= 56). These
symptoms included dizziness (50% of patients), increased dream-
ing/vivid dreams (35%), fatigue (30%), nausea/vomiting (30%),
headache (25%), anxiety/agitation (25%), paresthesia (15%),
insomnia (10%), diarrhea (10%), visual disturbances (10%), fever
(10%), tremor (5%), irritability (5%), and chills (5%). In addi-
tion to these symptoms, in an assessment of 87 patients who
had their treatment interrupted for 4–7 days in a double-blind
placebo study, Hindmarch et al. (2000) also reported greater cog-
nitive deficits, poorer quality of sleep and increased depressive
symptoms associated with paroxetine discontinuation, symptoms
which were not evident in patients ceasing fluoxetine, sertraline,
or citalopram treatment.
To date, there is no evidence to suggest that the length of SSRI
treatment is associated with the development of more symptoms
or with the severity of those symptoms (Rosenbaum et al., 1998;
Michelson et al., 2000; Baldwin et al., 2007). However, several stud-
ies suggest that an abrupt interruption of treatment results in more
symptoms of the discontinuation syndrome compared to a gradual
tapering of the drug (van Geffen et al., 2005; Himei and Okamura,
2006; Murata et al., 2010). This suggests that the incidence, timing,
and severity of SSRI discontinuation symptoms may be related to
plasma elimination characteristics of each drug. In view of this,
Michelson et al. (2000) found a statistically significant relationship
between the percentage reduction in plasma concentration of the
drug and the appearance of discontinuation symptoms resulting
from placebo substitution across all drug groups (fluoxetine, ser-
traline, and paroxetine). Comparing drug concentrations before
and after placebo substitution, Henry et al. (2000) found that
lower steady-state brain levels of paroxetine (but not fluoxetine)
after placebo substitution were associated with greater risk for
discontinuation-related adverse events. Overall, discontinuation
symptoms are more frequent after the abrupt cessation of drugs
with shorter half-lives (Rosenbaum et al., 1998; Bogetto et al., 2002;
Judge et al., 2002; Baldwin et al., 2007). However, that relationship
may not be an absolute predictor. Indeed, despite paroxetine hav-
ing a similar half-life to that of fluvoxamine, the rate of withdrawal
reactions for the latter drug is 10 times lower (Price et al., 1996).
For example, in the 46 patients with discontinuation symptoms
reviewed by Black et al. (2000), paroxetine was stopped in 65%
Table 1 | Pharmacokinetic and pharmacological parameters of SSRIs (adapted from Hiemke and Hartter, 2000; Owens et al., 1997, 2001;Tatsumi
et al., 1997).
Compounds Half-life
(mean)
SERT
(human)
5-HT1A
(rat)
5-HT2A
(rat)
5-HT2C
(porcine)
NET
(human)
DAT
(human)
Muscarinic
(human)
Fluvoxamine 15 h K D: 2.2, K i:2.3 n.d. n.d. K i:5786 K D: 1300, K i:1427 K D: 9200, K i:16790 K i:31200
Paroxetine 20 h K D: 0.13, K i:0.10 K i:21168 K i:6320 K i:9034 K D: 40, K i:45 K D: 490, K i:268 K i:72
Sertraline 26 h K D: 0.29, K i:0.26 K i:3663 K i:2207 K i:2298 K D: 420, K i:714 K D: 25, K i:22 K i:427
Citalopram 36 h K D: 1.16, K i:1.6 n.d. n.d. K i:2051 K D: 4070, K i:6190 K D: 28100, K i:16540 K i:1430
Fluoxetine 1–4 days K D: 0.81, K i:1.1 K i:8313 K i:141 K i:72 K D: 240, K i:599 K D: 3600, K i:3764 K i:702
Desmethylsertraline 2–3 days K D: 3.0 n.d. n.d. n.d. K D: 390 K D: 129 n.d.
Norfluoxetine 7–15 days K D: 1.47 n.d. n.d. n.d. K D: 1426 K D: 420 n.d.
Equilibrium dissociation (KD) and inhibition (Ki) constants for binding at serotonin, norepinephrine and dopamine transporters (SERT, NET, and DAT, respectively) and
several selected neurotransmitter receptors were determined using radioligand binding assays. n.d.: not determined.
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of these cases compared to only 7% of cases with fluvoxamine.
To date, there are no double-blind trials with placebo substitu-
tion comparing the effects of discontinuation from paroxetine
and fluvoxamine, and the higher number of reports of withdrawal
reactions with paroxetine is likely to reflect the greater prescription
rate of paroxetine over fluvoxamine (Lockhart and Guthrie, 2011).
Other factors (i.e., pharmacological) could also contribute to the
high frequency of discontinuation syndrome with paroxetine.
Notably, paroxetine has significant off-target effects, includ-
ing an affinity for cholinergic receptors similar to the tricyclic
antidepressants (Owens et al., 1997, 2001), raising the possibil-
ity for a cholinergic rebound during discontinuation. Fujishiro
et al. (2002) further demonstrated that the ability of paroxetine to
induce an anticholinergic effect in mice was similar to that of tri-
cyclic antidepressants, whereas fluvoxamine was much less potent
in that regard. Paroxetine also exhibits moderately high affinity
for the norepinephrine transporter, unlike other SSRIs (Tatsumi
et al., 1997). In comparison, the longer half-lives of the active
compounds of fluoxetine and sertraline may be the reason under-
lying fewer symptoms of the discontinuation syndrome. However,
as raised previously, the major limitation of most of the clinical
studies examining the discontinuation syndrome is the restric-
tion of treatment interruption to only few days, when longer
periods (i.e., weeks) might be more suitable for the study of fluox-
etine withdrawal. Finally, whether or not the pharmacodynamic
characteristics of a drug could also help to explain the clinical
observations remains to be addressed. For instance, fluoxetine
is also a 5-HT2C receptor antagonist (Sanchez and Hyttel, 1999)
with affinity for 5-HT2A/2C receptors (see Table 1), whereas sertra-
line is the sole SSRI which also inhibits the dopamine transporter
(Tatsumi et al., 1997).
The discontinuation syndrome has been reported in relation to
nearly every SSRI, although there are increased reports of occur-
rence in patients ceasing treatment of paroxetine. However, the full
extent of discontinuation syndrome might only emerge if future
studies are designed to take into account the pharmacokinetics of
the drug and availability of its active metabolite. Double-blind tri-
als with placebo substitution have yet to be undertaken to directly
compare the effects of discontinuation from SSRIs with shorter
half-lives (i.e., paroxetine and fluvoxamine). Overall, the cru-
cial question of whether the discontinuation syndrome is equally
related to the lack of specificity and/or the neurobiology related
to the half-life of the SSRI remains unclear. Potential genetic-drug
interactions should also be systematically assessed in future stud-
ies. Indeed, a recent clinical study suggested a possible involvement
of the C(-1019)G polymorphism of the serotonin 5-HT1A receptor
gene in the occurrence of paroxetine discontinuation syndrome, as
patients with the−1019C allele experienced paroxetine discontin-
uation syndrome more frequently than patients who were−1019G
homozygous (Murata et al., 2010).
ANIMAL STUDIES
MECHANISMS OF ACTION OF SSRIs
Numerous laboratories have studied the effects of SSRIs on the
serotonergic system, mainly investigating on the pharmacologi-
cal characteristics of these drugs (Table 1). For example, using
intracerabral microdialysis in conscious rodents, extracellular
concentrations of serotonin have been reported to be increased
following acute administration of fluoxetine (Hervas and Arti-
gas, 1998), citalopram (Rea et al., 2010), or sertraline (Kitaichi
et al., 2010). Further, Sharp et al. (1997) showed that paroxetine
induced a larger increase in extracellular serotonin in the frontal
cortex when serotonin autoreceptors on both the somatodendrites
(5-HT1A) and nerve terminals (5-HT1B) were blocked. Inciden-
tally, the acute effects of SSRIs on serotonin neurotransmission
are controlled by several feedback mechanisms, which include 5-
HT1A and 5-HT1B/1D autoreceptors (Malagie et al., 2001; Pullar
et al., 2004) as well as postsynaptic 5-HT2 receptors (Boothman
et al., 2003; Cremers et al., 2004; Calcagno et al., 2009). Recent
discoveries suggest an unexpected complexity in the mechanisms
controlling the activity of serotonin neurons (Sharp et al., 2007).
Notably, and particularly relevant to this review, antidepres-
sant drugs typically require chronic administration (i.e., several
weeks) to achieve therapeutic efficacy. This delay is thought to
partly reflect the time required for autoreceptors to desensitize
so as to facilitate serotonin neurotransmission (Kreiss and Lucki,
1995). Rather than the desensitization per se, Le Poul et al. (1995)
suggested that the progressive increase in the number of seroton-
ergic neurons with desensitized 5-HT1A autoreceptors may play a
critical role in the slow development of the antidepressant actions
of SSRIs. Extensive research has been done to study the changes
to serotonergic signaling induced by chronic SSRI administration
(summarized in Table 2).
Although it was initially thought that the antidepressant effects
of SSRIs were solely attributable to an increase in brain sero-
tonin, more recent evidence suggests that a sustained increase
in serotonin levels (at least within the hippocampus) does not
appear to be required for the beneficial anxiolytic/antidepressant-
like effects of chronic fluoxetine (Popa et al., 2010). Studies have
now shown that SSRIs modulate other neurochemical signal-
ing systems in the brain such as noradrenaline and dopamine.
For instance, paroxetine was reported to increase extracellular
levels of noradrenaline in the hippocampus of rats that had
received repeated administration of the drug (Hajos-Korcsok et al.,
2000). Similarly, chronic (but not acute) treatment with fluoxe-
tine potentiates dopamine D2/D3 receptor function (Collu et al.,
1997; Dziedzicka-Wasylewska et al., 2002). Therefore, it has now
become evident that in addition to effects at receptors regulating
monoamine release (e.g., 5-HT1, 5-HT2, andα-2 adrenergic recep-
tors), multiple targets (e.g., glutamate/GABA, peptidergic systems,
neurotrophic factors, hypothalamic-pituitary-adrenal axis, etc.)
are likely to be involved in the mechanism of action of SSRIs
(Schechter et al., 2005; Renoir et al., 2012). With that in mind,
we next review the effects of SSRI treatment discontinuation in
animal models. Most of these reports have focused on the sero-
tonergic system. However, as mentioned, there is scope for future
studies to assess non-serotonin signaling pathways in relation to
the SSRI discontinuation syndrome.
EFFECTS OF SSRI TREATMENT DISCONTINUATION IN ANIMAL MODELS
In this section we first focus on the few animal studies which
report behavioral changes after cessation of SSRI treatment (versus
behavioral changes found during treatment), followed by a dis-
cussion of the potential molecular mechanisms involved. Despite
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the relatively consistent cluster of clinical symptoms observed in
the SSRI discontinuation syndrome, few animal studies have been
conducted to explicitly examine the effects of withdrawal from
chronic SSRI treatment. Moreover, most of those studies have used
fluoxetine, despite a low incidence of discontinuation syndrome
associated with this specific SSRI in the clinic.
In one animal study, contrasting with the reduction of locomo-
tor activity observed during chronic administration of fluoxetine
(30 mg/kg/day for 5 days), fluoxetine-treated rats showed a signif-
icant increase in locomotor activity upon discontinuation (Bjork
et al., 1998). Notably, this “rebound effect” was only observed dur-
ing the first 4 h following the first “missed” dose, and not during
the subsequent washout period. These findings suggest that upon
cessation of chronic fluoxetine, rats showed an increase in activ-
ity resembling withdrawal behavior, in line with the symptoms
of anxiety/agitation reported by some patients who develop the
discontinuation syndrome. Hyperactivity in response to abrupt
fluoxetine discontinuation may result from fluoxetine’s effects
on the dopaminergic system, specifically in the ventral tegmen-
tal area and in the nucleus accumbens. In that regard, Gardier
et al. (1994) found that chronic fluoxetine treatment caused a per-
sistent decrease in striatal dopamine levels lasting up to 14 days
after treatment discontinuation. Other reports have provided fur-
ther evidence of changes in dopaminergic signaling during SSRI
discontinuation. By measuring the spontaneous firing rate of hip-
pocampal CA1 neurons, Bijak and Smialowski (1988) found that
the excitatory reaction evoked by the selective D1 receptor ago-
nist SKF-38393 was potentiated following repeated citalopram
administration, and was further increased after drug withdrawal.
Similarly, the enhancement of dopaminergic synaptic modula-
tion (through hippocampal D1 receptor upregulation) induced by
chronic fluoxetine was maintained for 1 month after drug with-
drawal (Kobayashi et al., 2012). The mesolimbic dopamine system
is thought to be involved in the behavioral effects of antidepres-
sants (Collu et al., 1997), as well as in the withdrawal syndrome
following cessation of drugs of abuse (Hu, 2007; D’Souza and
Markou, 2010; Radke et al., 2011). However, another animal study
found no change in intracranial self-stimulation threshold during
withdrawal from chronic fluoxetine treatment (Lin et al., 1999).
This finding suggests that there is no change in central reward
function after cessation of fluoxetine treatment, and therefore
that SSRI discontinuation syndrome and withdrawal symptoms in
drug addiction may involve distinct pathways. However, since sev-
eral clinical observations point to the existence of tolerance phe-
nomena during antidepressant treatment in some cases (Fava and
Offidani, 2011), further animal research is required to determine
the dependence potential of the various types of antidepressant
drugs.
In an attempt to compare and contrast the mechanisms
underlying the effects of continuous SSRI administration against
abrupt SSRI discontinuation, Bosker and colleagues measured the
acoustic startle response of rats that had either been receiving
2 weeks of citalopram or had undergone 48 h of discontinuation
from citalopram treatment (Bosker et al., 2010). Behavioral assess-
ments started 2 days after the removal of osmotic mini pumps filled
with either saline or 50 mg/ml citalopram. Habituation was sig-
nificantly diminished in the 48-h discontinuation group, as their
acoustic startle response (a transient motor response to an unex-
pected, intensive stimulus) was significantly greater compared to
the rats receiving ongoing 2 week citalopram treatment. Exag-
gerated acoustic startle response has been previously linked to
anxiety-like behaviors in rodents (Plappert and Pilz, 2002). There-
fore, the findings of Bosker et al. (2010) suggest a higher level of
anxiety in the citalopram discontinuation group, which is similar
to the increased incidence of anxiety in patients with the SSRI dis-
continuation syndrome. An increased reactivity to acoustic stimuli
in rats has been linked to long-term depletion of serotonin in the
brain (Tanke et al., 2008). Consistent with that notion, Bosker
et al. (2010) found that an index of serotonin turnover [the ratio
of 5-hydroxyindoleacetic acid to serotonin (5-HIAA/5-HT)] was
increased after the 48-h washout period following chronic citalo-
pram treatment, while chronic treatment exerted no significant
effect on serotonin turnover. This finding is in agreement with
an earlier study reporting that levels of the serotonin metabolite
5-HIAA are increased during withdrawal from chronic fluoxetine
(30 mg/kg/days for 21 days), and are sustained at levels exceed-
ing control levels (by 30–50%) for at least 14 days after cessation
of chronic fluoxetine treatment (Trouvin et al., 1993). Similarly,
while serotonin turnover rates were significantly decreased dur-
ing the first 24 h after the last injection of a 3-week treatment
with fluoxetine (6.9 mg/kg/day), turnover rates increased signifi-
cantly after an 8-day washout period (Stenfors and Ross, 2002).
Behavioral changes in relation to increased serotonin turnover
rates during drug washout were not examined. Similarly, as Bosker
et al. (2010) assessed the biochemical consequences and behav-
ioral effects of citalopram discontinuation in separate cohorts
of animals, no direct comparisons between increased serotonin
turnover and increased acoustic startle response could be made.
Further behavioral testing is required to validate the finding of
a greater acoustic startle response, using additional tests such
as the elevated-plus maze, the light-dark box, etc. Finally, based
on the low incidence of the discontinuation syndrome reported
in patients treated with citalopram or fluoxetine, it is likely that
studying the role of serotonin turnover in the behavioral effects
of long-term paroxetine administration versus discontinuation
might give different results. Indeed, likely resulting from the accu-
mulation of its main active metabolite norfluoxetine after 14 days
of chronic administration, only fluoxetine (but not paroxetine)-
treated animals exhibited reduced brain serotonin levels after a
1-week washout period (Caccia et al., 1993).
Despite the fact that adaptive changes in 5-HT1A/1B autorecep-
tors are critically involved in the mechanistic actions of SSRIs (as
discussed in See Mechanisms of Action of SSRIs), many preclin-
ical studies of SSRI withdrawal have focused on serotonin levels.
As such, a lack of understanding of any possible adaptive func-
tional changes to serotonin receptors remains. Raap et al. (1999)
reported that 5-HT1A receptors located in the hypothalamus of
rats are desensitized following a 2-week treatment with fluoxetine,
an effect which lasted for at least 60 days. Given the implications of
the fronto-cortical regions and the hippocampus in the withdrawal
symptoms, and based on altered serotonin metabolism mentioned
in the previous section, further work is required to improve our
understanding of the extent of 5-HT1A receptor adaptation in
the brain following SSRI withdrawal. One study suggested that
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molecular changes follow a rapid time course, requiring 3–14 days
of washout to reverse the reductive effects of chronic fluoxetine
and paroxetine treatment on pre-synaptic 5-HT1B receptor mRNA
levels in rat dorsal raphe nucleus (Anthony et al., 2000).
Although not the main focus of the studies, two separate groups
reported the behavioral effects of long-term administration of
paroxetine compared to the behavioral effects of discontinuation
of paroxetine treatment (Gervasoni et al., 2002; Elizalde et al.,
2008). It was found that the anxiolytic-like effects of chronic
paroxetine (10 mg/kg/day for 3 weeks) were no longer observed
after a 2-week washout period (Elizalde et al., 2008). The loss
of this drug effect is interesting considering the development of
symptoms of anxiety in patients with the discontinuation syn-
drome. On the other hand, the antidepressant effect of paroxetine
and the amelioration of cognitive deficits were maintained even
after a 2-week washout period, which does not correspond with
increased incidence of depressive symptoms in individuals expe-
riencing the discontinuation syndrome. While this study was not
designed to explicitly examine the discontinuation syndrome, to
our knowledge this is the sole preclinical study assessing the longer
term behavioral effects of halting chronic SSRI treatment in an ani-
mal model of depression (i.e., chronic mild stress paradigm). As
the eventual development of the discontinuation syndrome was
not the focus of the study, other behavioral parameters relevant to
the clinical symptoms of the syndrome, such as changes in sleep
patterns/architecture, were not examined. Gervasoni et al. (2002)
reported that in rats, a reduction in the amount of REM sleep, as
well as an increase in the duration of REM sleep episodes, was asso-
ciated with chronic treatment with paroxetine (5 mg/kg/day for
21 days), rather than to discontinuation of treatment, as these sleep
changes were not observed after a 24-h washout period. Since sleep
disturbances are often reported in patients with discontinuation
symptoms, it is of importance for future animal studies examining
the discontinuation syndrome to assess sleep patterns/architecture
as relevant outcomes.
Overall, the number of preclinical studies looking at the effects
of SSRI after a washout period remains very limited. Many such
reports were published prior to the recognition of SSRI discontin-
uation syndrome as a clinical condition, and were mainly intended
to study the mechanism of action of the SSRI while having the drug
on board. To date, clear discontinuation-like behaviors in animal
models have not yet been reported. However, it should be noted
that we suggest that a flaw of these previous studies did not use
animal models of depression. In addition, it is of importance that
future studies consider an appropriate time point for assessment
based on the half-life of the drug of interest. It is also of impor-
tance for future studies to examine the effects of paroxetine, as
this SSRI has been implicated in numerous clinical cases of the
discontinuation syndrome (Bogetto et al., 2002; Judge et al., 2002;
Baldwin et al., 2007). The animal studies performed to date have
focused on measures of tissue serotonin levels; as it is now clear
that other pathways are involved in the mechanistic actions of
SSRIs, future investigations should be broadened to include an
examination of these additional actions. The complex nature of
SSRI discontinuation syndrome, in terms of the variety of subtle
symptoms that may present at the clinic, poses a challenge for pre-
clinical studies, and there is a need for appropriate animal models
to be developed in order to facilitate further study of the behavioral
aspects of this condition. As mentioned, the majority of studies to
date have been based on “normal” animals, whereas the clinical
population who develop the discontinuation syndrome are typi-
cally taking SSRIs for treatment of depression, anxiety, etc. As such,
future studies of the SSRI discontinuation syndrome in rodents
should encompass well-established animal models of depression,
chronic SSRI treatment, followed by an appropriate period of drug
withdrawal.
DISCUSSION AND CONCLUSION
Although initial observations relied only on case reports, there is
now a substantial body of clinical evidence suggesting that, in some
cases, SSRIs may be associated with a withdrawal response when
halted after a period of regular use. The existence of these symp-
toms, known as the SSRI discontinuation syndrome, has now been
confirmed by a number of well-controlled studies (i.e., double-
blind randomized placebo-controlled design, in which treatment
is followed by a prospectively defined discontinuation period).
These studies suggest that the best route of action for cessation of
SSRI treatment is to taper down the dose of the medication rather
than abrupt termination, as tapering is likely to decrease the pos-
sibility of the occurrence of discontinuation symptoms. Due to
the broad range of symptoms which can develop as part of the
discontinuation syndrome, prior to drug initiation, patients and
caregivers need to be provided with adequate education and real-
istic, objective appraisals of possible outcomes which can develop
during and following antidepressant treatment.
The current evidence suggests that the discontinuation syn-
drome is dependent on the SSRI half-life, with more reports of
symptoms occurring in patients treated with paroxetine compared
to other SSRIs. However, studies designed to assess the onset of
discontinuation syndrome, and how the syndrome coincides tem-
porally with pharmacokinetic withdrawal, are still lacking. Such
studies are critical in order to draw conclusions when compar-
ing SSRIs with short versus long half-lives. It is currently unclear
as to whether the discontinuation syndrome is equally related to
the pharmacological properties of a given SSRI, and/or its half-
life. Future studies could also examine possible associations of
the syndrome with clinical characteristics, as one study reported
that the discontinuation syndrome was more common in patients
with earlier onset of dysthymic disorder, and was also more com-
mon in females (Bogetto et al., 2002). On the other hand, Baldwin
et al. (2007) reported no difference in discontinuation symptoms
in patients with depression compared to patients with anxiety
disorders. Future clinical investigations need to have enough statis-
tical power to enable examination of within-group comparisons.
Current understanding of the pathophysiology associated with
the SSRI discontinuation syndrome remains largely speculative
(Blier and Tremblay, 2006; Delgado, 2006). In fact, the sole clin-
ical investigation looking at the possible chemical and molecular
mechanisms underlying the SSRI discontinuation syndrome was
based on a single subject (Kaufman et al., 2003).
Notably, not all patients treated with SSRIs (which repre-
sents a very heterogeneous population) experience discontinua-
tion symptoms. In that regard, a recent clinical study indicated
a possible involvement of the C(-1019)G polymorphism of the
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serotonin 5-HT1A receptor gene in the occurrence of paroxetine
discontinuation syndrome (Murata et al., 2010). Whether the
development of discontinuation symptoms has a genetic compo-
nent requires additional studies to provide more conclusive results.
The use of genetic animal models might be able to shed light
in that regard. Interestingly, using mice with higher (1A-High)
or lower (1A-Low) autoreceptor levels, Richardson-Jones et al.
(2010) found a negative relationship between 5-HT1A autorecep-
tor level and response to antidepressants. Further studies looking
at the effects of 5-HT1A receptor function on vulnerability to
the discontinuation syndrome are of interest. Most of the ani-
mal studies performed thus far have naturally focused on the
serotonergic system, and have mainly used fluoxetine, despite
the fact that this specific SSRI has been associated with a lower
incidence of discontinuation syndrome in the clinic. However,
based on the numerous targets known to be changed adaptively
during chronic treatment with SSRIs in animal models, further
studies assessing non-serotonergic pathways would be worthwhile.
Finally, preclinical studies using appropriate animal models of
anxiety/depression are still lacking when it comes to the study
of SSRI discontinuation.
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